NasdaqGS - Nasdaq Real Time Price USD

Revolution Medicines, Inc. (RVMD)

Compare

41.78

-2.64

(-5.94%)

At close: January 10 at 4:00:01 PM EST

42.00

+0.22

+(0.53%)

After hours: January 10 at 6:35:43 PM EST

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. PT. To access the live webcast of the present

GlobeNewswire 5 days ago

RVMD
-5.94%
RVMDW
One Revolution Medicines Insider Raised Their Stake In The Previous Year

Viewing insider transactions for Revolution Medicines, Inc.'s ( NASDAQ:RVMD ) over the last year, we see that insiders...

Simply Wall St. 30 days ago

RVMD
-5.94%
RVMDW
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Underwriters’ full exercise of option brings gross proceeds to $862.5 millionREDWOOD CITY, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the closing of its underwritten public offering of 16,576,088 shares of its common stock at a public offering price of $46.00 per share, before underwriting discounts and commissions, and, in lieu of shar

GlobeNewswire last month

RVMD
-5.94%
RVMDW
Revolution Medicines price target raised to $87 from $82 at Guggenheim

Guggenheim analyst Michael Schmidt raised the firm’s price target on Revolution Medicines (RVMD) to $87 from $82 and keeps a Buy rating on the shares citing increased odds of success assumptions in second-line non-small cell lung cancer after the company provided a clinical data update on its RAS inhibitor pipeline that the the firm believes was “generally positive and further de-risks RVMD’s clinical development plans in PDAC, NSCLC, and CRC.” Published first on TheFly – the ultimate source for

TipRanks last month

RVMD
-5.94%
RVMDW
Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the pricing of 14,130,436 shares of its common stock at a public offering price of $46.00 per share, before underwriting discounts and commissions, and, in lieu of shares of common stock, to certain investors, pre-funded warrants to purchase 2,173,917 shares of common stock at a p

GlobeNewswire last month

RVMD
-5.94%
RVMDW
Revolution Medicines Announces Commencement of Public Offering of Common Stock

REDWOOD CITY, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it has commenced an underwritten public offering to sell up to $600.0 million of shares of its common stock. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines intends to grant the underwriters a 30-day option to pur

GlobeNewswire last month

RVMD
-5.94%
RVMDW
Revolution Medicines Reports Early Data Supporting Ongoing Study of Cancer Therapies

Revolution Medicines (RVMD) shares declined 9% in recent Monday trading after the company presented

PREMIUM
MT Newswires last month

RVMDW
Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Compelling Phase 1/1b update on RMC-6236 monotherapy in second-line metastatic pancreatic ductal adenocarcinoma supports ongoing Phase 3 RASolute 302 clinical trial Phase 1/1b proof-of-concept for RMC-6236 monotherapy in previously treated non-small cell lung cancer supports Phase 3 RASolve 301 clinical trial expected to be initiated in Q1 2025 Favorable initial safety profile for combination of pembrolizumab with either RMC-6236 or RMC-6291 supports continued evaluation in non-small cell lung c

GlobeNewswire last month

RVMD
-5.94%
RVMDW
Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will host an investor webcast to provide clinical updates from its RAS(ON) inhibitor portfolio. The webcast will take place at 8:00 a.m. Eastern Time on Monday, December 2, 2024. To access the webcast, click here. An archived replay will be available on the “Events & Prese

GlobeNewswire last month

RVMD
-5.94%
RVMDW
Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight

Insightful Analysis of Revolution Medicines Inc's Financial Health and Market Position

GuruFocus.com 2 months ago

RVMDW
Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

Revolution Medicines Inc (RVMD) reports promising clinical progress and robust cash reserves, despite increased R&D and administrative costs.

GuruFocus.com 2 months ago

RVMDW
Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

Phase 3 pivotal trial underway evaluating RMC-6236 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), supported by compelling clinical profile First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging safety, tolerability and antitumor activity in patients with PDAC harboring a KRAS G12D mutation Company on track to provide update on lung cancer programs in the fourth quarter of 2024 Revolution Medicines to hold webcast today at 4:30 p.m.

GlobeNewswire 2 months ago

RVMD
-5.94%
RVMDW
Revolution Medicines to Participate in Upcoming Investor Conferences

REDWOOD CITY, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at Guggenheim's Inaugural Healthcare Innovation Conference and the UBS Global Healthcare Conference. Details of the company’s participation are as follows: Guggenheim's Inaugural

GlobeNewswire 2 months ago

RVMD
-5.94%
RVMDW
Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

REDWOOD CITY, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that it will report financial results for the third quarter 2024 on Wednesday, November 6, 2024, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), members of Revolution Medicines’ senior management team will host a webcast to discuss the financial re

GlobeNewswire 2 months ago

RVMD
-5.94%
RVMDW
Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

First clinical results for RMC-9805, a RAS(ON) G12D-selective inhibitor, demonstrate encouraging tolerability and antitumor activity in patients with PDAC Investor webcast to be held Friday, October 25 at 12:00 p.m. Eastern Time (ET) REDWOOD CITY, Calif., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced preliminary safety and antitumor data for RMC-9805, its RAS(O

GlobeNewswire 2 months ago

RVMD
-5.94%
RVMDW
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Encouraging progression-free survival and overall survival profile Safety findings consistent with previously reported data, no new safety signals observed Investor webcast to be held Friday, October 25 at 12:00 p.m. Eastern Time (ET) REDWOOD CITY, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced encouraging antitumor activity and safety/tolerability data

GlobeNewswire 2 months ago

RVMD
-5.94%
RVMDW
Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the first patient has been dosed in RASolute 302, a Phase 3 registrational study of RMC-6236, a RAS(ON) multi-selective inhibitor, in patients with previously treated, metastatic pancreatic ductal adenocarcinoma (PDAC). RASolute 302 is a global, randomized, open-label Phase 3

GlobeNewswire 2 months ago

RVMD
-5.94%
RVMDW
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

Pancreatic ductal adenocarcinoma (PDAC) data from RMC-6236 (RAS(ON) multi-selective inhibitor) and RMC-9805 (RAS (ON) G12D-selective inhibitor) monotherapy studies to be featured in two late-breaking presentationsREDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced seven oral and poster presentations will be featured at the 2024 AAC

GlobeNewswire 3 months ago

RVMD
-5.94%
RVMDW
Revolution Medicines, Inc. (RVMD): Among Hedge Funds’ Top Biotech Stock Picks

We recently compiled a list of the 10 Largest Biotech Hedge Funds and Their Top Stock Picks. In this article, we are going to take a look at where Revolution Medicines, Inc. (NASDAQ:RVMD) stands against the other biotech stocks. The ability to successfully make money through investment requires deep thinking and analysis. Even then, it’s not […]

Insider Monkey 3 months ago

RVMDW
Revolution Medicines First Half 2024 Earnings: US$1.51 loss per share (vs US$1.64 loss in 1H 2023)

Revolution Medicines ( NASDAQ:RVMD ) First Half 2024 Results Key Financial Results Net loss: US$249.2m (loss widened by...

Simply Wall St. 5 months ago

RVMD
-5.94%
RVMDW

Performance Overview

Return	RVMD	S&P 500
YTD	-3.22%	-1.35%
1-Year	+46.49%	+22.51%
3-Year	+82.13%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Revolution Medicines, Inc. (RVMD)

Revolution Medicines to Present at 43rd Annual J.P. Morgan Healthcare Conference

One Revolution Medicines Insider Raised Their Stake In The Previous Year

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Revolution Medicines price target raised to $87 from $82 at Guggenheim

Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

Revolution Medicines Announces Commencement of Public Offering of Common Stock

Revolution Medicines Reports Early Data Supporting Ongoing Study of Cancer Therapies

Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024

Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight

Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress

Revolution Medicines to Participate in Upcoming Investor Conferences

Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024

Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma

Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast

Revolution Medicines, Inc. (RVMD): Among Hedge Funds’ Top Biotech Stock Picks

Revolution Medicines First Half 2024 Earnings: US$1.51 loss per share (vs US$1.64 loss in 1H 2023)

Performance Overview